Rice Hall James & Associates LLC Sells 6,785 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Rice Hall James & Associates LLC reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 110,632 shares of the company's stock after selling 6,785 shares during the quarter. Rice Hall James & Associates LLC owned about 0.11% of Neurocrine Biosciences worth $15,101,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Peregrine Capital Management LLC boosted its stake in Neurocrine Biosciences by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 64,840 shares of the company's stock valued at $8,851,000 after buying an additional 1,159 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Neurocrine Biosciences by 13.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,078 shares of the company's stock valued at $557,000 after acquiring an additional 487 shares during the last quarter. Sanctuary Advisors LLC boosted its position in shares of Neurocrine Biosciences by 7.1% during the 4th quarter. Sanctuary Advisors LLC now owns 8,191 shares of the company's stock valued at $1,118,000 after purchasing an additional 542 shares in the last quarter. Capital Performance Advisors LLP grew its stake in shares of Neurocrine Biosciences by 1,101.4% in the 4th quarter. Capital Performance Advisors LLP now owns 1,730 shares of the company's stock worth $236,000 after purchasing an additional 1,586 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 11.7% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,499 shares of the company's stock worth $341,000 after purchasing an additional 261 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock traded up $1.93 during trading on Thursday, hitting $116.19. 948,350 shares of the stock traded hands, compared to its average volume of 1,307,669. The stock has a market cap of $11.58 billion, a P/E ratio of 35.31, a PEG ratio of 0.77 and a beta of 0.33. The company has a fifty day moving average price of $136.97 and a two-hundred day moving average price of $129.81. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company's stock, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matt Abernethy sold 2,558 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.86, for a total value of $298,927.88. Following the transaction, the chief financial officer now directly owns 34,775 shares in the company, valued at approximately $4,063,806.50. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 236,600 shares of company stock worth $34,348,261. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Piper Sandler reissued an "overweight" rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Barclays boosted their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a research report on Monday, December 23rd. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Finally, UBS Group lifted their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.